EUVIMEDOtkrijte EUVIMED
CrossrefInformacijska kartica

Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy

Zan Chen, Wei Xu

Precision Radiation Oncology · 2019

DOI: 10.1002/pro6.1069 ↗
SažetakBibliografski podaci

Sažetak

Abstract Radiotherapy is an effective treatment for many cancer patients to eliminate malignant cells and increase survival rate. However, cancer cells can develop resistance in response to radiation through activation of signaling pathways that promote cell cycle progression, DNA damage response, cell survival, and inflammation. Various combination therapies are developed to sensitize radiotherapy by targeting key signaling proteins involved in radioresponse. The past decade has seen significant advances in the knowledge of ubiquitin signaling in cancer biology. Developing E3 ubiquitin ligase‐related molecules as novel strategies to cure cancer has become an emerging field. This review briefly discusses the potential of targeting diverse E3 ubiquitin ligases as promising strategies for radiosensitization in cancer.

Znanje koje odgovara vašem radu.

Od besplatnog početka i osobnog pretraživanja literature do potpunog paketa Research Suite.

Prikaži tarife →

Jesu li uključeni svi cjeloviti tekstovi izdavača?

Ne. Bibliografski zapisi, sažeci i cjeloviti tekstovi različiti su sadržaji. Hoće li cjeloviti tekst biti dostupan ovisi o izvoru, Open Accessu i vašim postojećim licencama. Tarifa EUVIMED ne zamjenjuje dodatna izdavačka prava.

Prikaži tarife →